This new patent addresses the composition and methods of a new compound described as a calcium-activated potassium channel opening agent for topical treatment of hair loss. DS Healthcare had filed its first patent in October 2013 for its prescription hair loss product currently under development.
DS Healthcare president and CEO Daniel Khesin noted that the company believes this newly filed patent-pending molecule offers a more effective over-the-counter hair loss solution than the US Food and Drug Administration approved topical minoxidil for hair regrowth.
"DS Healthcare’s proprietary hair loss formulations are a tremendous asset and we are building our IP portfolio including patents, as well as trademarks for our industry-leading brands. While sales of our over-the-counter products continue to grow driven by strong consumer demand, in parallel we are developing our first prescription hair loss product," Khesin added.